The Medicines Company: Investor & Analyst Day (The Medicines Company) - Nov 8, 2014 - "MDCO-216 (ApoA1- Milano/POPC) Phase I clinical trial completed successfully"; "Up to 4 fold increase in ABCA1 efflux compared with baseline"; "ABCA1 efflux was maximally increased by 20 mg/kg in CAD patients"; "The ApoA1-Milano lipid phenotype of low HDL-C and raised TG was observed"; "MDCO-216 was well tolerated at all doses"
P1 data • Dyslipidemia
|